The cost of cancer care-balancing our duties to patients versus society: Are they mutually exclusive?

Oncologist

Volumn 18, Issue 4, 2013, Pages 347-349

  Kumar, Pallavi ^a   Moy, Beverly ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Cancer care; Decision making; Ethical issues; Health care costs; Resource allocation

Indexed keywords

DOXORUBICIN; LAPATINIB; METHOTREXATE; PERTUZUMAB; TRASTUZUMAB;

ALGORITHM; CONFLICT; DECISION MAKING; DRUG COST; EDITORIAL; EVIDENCE BASED PRACTICE; GROSS NATIONAL PRODUCT; HEALTH CARE; HEALTH CARE COST; HUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL;

COST-BENEFIT ANALYSIS; DECISION MAKING; HEALTH CARE COSTS; HUMANS; NEOPLASMS; PATIENTS;

EID: 84877041338     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0078     Document Type: Editorial

References (35)

1. Meropol NJ, Schulman KA. Cost of cancer care: Issues and implications. J Clin Oncol 2007;25:180-186.
2. Tangka FK, Trogdon JG, Richardson LC et al. Cancer treatment cost in the United States: Has the burden shiftedovertime? Cancer 2010;116:3477-3484.
3. Cancer Trends Progress Report-2011/2012 Update. Available at http://progressreport.cancer.gov. Accessed September 5, 2012.
4. Mariotto AB, Yabroff KR, Shao Y et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011;103:117-128.
5. Dinan MA, Curtis LH, Hammill BG et al. Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. JAMA 2010;303:1625-1631.
6. Zafar SY, Peppercorn JM, Schrag D et al. The financial toxicity of cancer treatment: Apilot study assessing outof- pocket expenses and the insured cancer patient's experience. The Oncologist 2013;18:381-390.
7. Brody H. Medicine's ethical responsibility for health care reform-The Top Five list. N Engl J Med 2010;362:283-285.
8. American Board of Internal Medicine. Choosing Wisely. Available at http://choosingwisely.org. Accessed September 21, 2012.
9. Farber NJ. Conflicts in the surgeon's duties to the patient and society. Thorac Surg Clin 2005;15:527-532.
10. The GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA 1994;271:1587-1592.
11. Rojas MP, Telaro E, Russo A et al. Follow-upstrategies for women treated for early breast cancer. Cochrane Database Syst Rev 2005(1):CD001768.
12. Rosselli Del Turco M, Palli D, Cariddi A et al. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial National Research Council Project on Breast Cancer follow- up JAMA 1994;271:1593-1597.
13. Schapira DV. Breast cancer surveillance-A cost-effective strategy. Breast Cancer Res Treat 1993;25:107-111.
14. Edelman MJ, Meyers FJ, Siegel D. The utility of follow-up testing after curative cancer therapy. A critical review and economic analysis. J Gen Intern Med 1997;12:318-331.
15. Baselga J, Bradbury I, Eidtmann H et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase3trial. Lancet 2012;379:633-640.
16. Baselga J, Cortes J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-119.
17. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-1791.
18. U.S. Food and Drug Administration. FDA approves new treatment for late-stage breast cancer. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm340704.htm. Accessed February 28, 2013.
19. Peppercorn J, Armstrong A, Zaas DW et al. Rationing in urologic oncology: Lessons from sipuleucel- T for advanced prostate cancer. Urol Oncol 2012 Feb 3 [Epub ahead of print].
20. Fojo T, Grady C. How much is life worth: Cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009;101:1044-1048.
21. Valgus J, Singer EA, Berry SR, Rathmell WK. Ethical challenges: Managing oncology drug shortages. J Oncol Pract 2013 (in press).
22. Keirns CC, Goold SD. Patient-centered care and preference-sensitive decision making. JAMA 2009;302:1805-1806.
23. Sackett DL, Rosenberg WM, Gray JA et al. Evidence based medicine: What it is and what it isn't. BMJ 1996;312:71-72.
24. Hasnain-Wynia R. Is evidence-based medicine patient-centered and is patient-centered care evidence-based? Health Serv Res 2006;41:1-8.
25. Brown R, Butow P, Wilson-Genderson M et al. Meeting the decision-making preferences of patients with breast cancer in oncology consultations: Impact on decision-related outcomes. J Clin Oncol 2012;30:857-862.
26. Street RL Jr., Voigt B. Patient participation in deciding breast cancer treatment and subsequent quality of life. Med Decis Making 1997;17:298-306.
27. Hack TF, Degner LF, Watson P et al. Do patients benefit from participating in medical decision making? Longitudinal follow-up of women with breast cancer. Psychooncology 2006;15:9-19.
28. Bruera E, Willey JS, Palmer JL et al. Treatment decisions for breast carcinoma: Patient preferences and physician perceptions. Cancer 2002;94:2076-2080.
29. Tariman JD, Berry DL, Cochrane B et al. Preferred and actual participation roles during health care decision making in persons with cancer: A systematic review. Ann Oncol 2010;21:1145-1151.
30. Stacey D, Bennett CL, Barry MJ et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2011;10: CD001431.
31. Oshima Lee E, Emanuel EJ. Shared decision making to improve care and reduce costs. N Engl J Med 2013;368:6-8.
32. Bullock AJ, Hofstatter EW, Yushak ML et al. Understanding patients' attitudes toward communication about the cost of cancer care. J Oncol Pract 2012;8:e50-e58.
33. The Patient Protection and Affordable Care Act. Available at http://www.gpo.gov/fdsys/pkg/BILLS-111hr3590enr/pdf/BILLS-111hr3590enr.pdf. Accessed March 19, 2013.
34. Emanuel E, Tanden N, Altman S et al. A systemic approach to containing health care spending. N Engl J Med 2012;367:949-954.
35. Moy B, Abernathy AP, Peppercorn JM. Core elements of the Patient Protection and Affordable Care Act and their relevance to the delivery of high-quality cancer care. ASCO 2012 Educational Book, Alexandria, VA: American Society of Clinical Oncology, 2012.